ECCO 2021 Highlights Podcast

  In this podcast, Medicom’s correspondent covers 4 presentations held at the European Crohn’s and Colitis Organisation (ECCO 2021), held virtually July 2-3 & 8-10, 2021. The topics discussed are: Biologics Updates: Ustekinumab and adalimumab both showed high efficacy in biologic-naïve patients with moderate-to-severe Crohn’s disease (CD). No significant difference in clinical remission rate was observed between the two therapies at 52 weeks of follow-up. The multicentre, randomised, blinded SEAVUE study was the first trial comparing these two biologics head-to-head in a population of CD patients. Improvements in Small Molecules: Induction of upadacitinib treatment in patients with moderate-to-severe ulcerative colitis (UC) led to higher clinical remission rates than placebo after 8 weeks. Moreover, all ranked secondary endpoints of the phase 3 U-ACCOMPLISH trial were met. The treatment was well tolerated and...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 10 August, 202118 August, 2021